Irritable Bowel Syndrome Clinical Trial
— BIOFEESOMATOOfficial title:
Neurovegetative Decoupling in the Visceral-brain Axis and Cognitive-emotional Vulnerability in Somatoform Disorders : Interest of Vagal Biofeedback
Evaluation of the physiological and clinical effects of the biofeedback training with patients suffering from somatoform disorders, depending on their neurovegetative profile related to a visceral-brain decoupling.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 2023 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Somatoform disorders (IBS or PNES) diagnosis must be established by the partner doctors - Participants must have home computer - Participants must be of the age of majority - Participants must be registered for social security - Participants must have signed an informed consent Exclusion Criteria: - Specially protected participants (under clauses L1121-5 and L1121-8 by the code of public health): juveniles, pregnant womens, nursing mothers, law's protection peoples - Participants suffering from a severe psychiatric disease needing specialised attention - Participants suffering from or have suffered from a severe disease causing autonomic dysfunctions (heart failure, asthma, blood disease, renal failure, peripheral neuropathy, vagotomy, thyroid disorder, alcoholism, liver disease, amyloidosis) - Participants taking medication which could be impact autonomic nervous system activity (anticholinergic, antiarrhythmics, clonidine, beta-blockers, tricyclic anti-depressants, metronidazole) - Participants placing under judicial or administrative supervisions - Participants were compensated more than 4500 euros because of his research protocol participation concerning human over the 12 months prior to the actual study - Participants being not be able to contact in emergency - Participants being in an exclusion period from another study |
Country | Name | City | State |
---|---|---|---|
France | University Hospital, Grenoble Alpes | Grenoble | Isère |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Grenoble | Laboratoire de Psychologie et NeuroCognition, Laboratoire interuniversitaire de psychologie : personnalité, cognition et changement social - LIP-PC2S |
France,
Bulut NS, Wurz A, Yorguner Kupeli N, Carkaxhiu Bulut G, Sungur MZ. Heart rate variability response to affective pictures processed in and outside of conscious awareness: Three consecutive studies on emotional regulation. Int J Psychophysiol. 2018 Jul;129:18-30. doi: 10.1016/j.ijpsycho.2018.05.006. Epub 2018 May 19. — View Citation
de Vroege L, Emons WHM, Sijtsma K, van der Feltz-Cornelis CM. Psychometric Properties of the Bermond-Vorst Alexithymia Questionnaire (BVAQ) in the General Population and a Clinical Population. Front Psychiatry. 2018 Apr 23;9:111. doi: 10.3389/fpsyt.2018.00111. eCollection 2018. — View Citation
Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available. — View Citation
Laborde S, Mosley E, Thayer JF. Heart Rate Variability and Cardiac Vagal Tone in Psychophysiological Research - Recommendations for Experiment Planning, Data Analysis, and Data Reporting. Front Psychol. 2017 Feb 20;8:213. doi: 10.3389/fpsyg.2017.00213. eCollection 2017. — View Citation
Mehling WE, Acree M, Stewart A, Silas J, Jones A. The Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2). PLoS One. 2018 Dec 4;13(12):e0208034. doi: 10.1371/journal.pone.0208034. eCollection 2018. — View Citation
Muller L, Spitz E. [Multidimensional assessment of coping: validation of the Brief COPE among French population]. Encephale. 2003 Nov-Dec;29(6):507-18. French. — View Citation
Sarason IG, Johnson JH, Siegel JM. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychol. 1978 Oct;46(5):932-46. doi: 10.1037//0022-006x.46.5.932. No abstract available. — View Citation
Schumann A, Kohler S, Brotte L, Bar KJ. Effect of an eight-week smartphone-guided HRV-biofeedback intervention on autonomic function and impulsivity in healthy controls. Physiol Meas. 2019 Jul 1;40(6):064001. doi: 10.1088/1361-6579/ab2065. — View Citation
Varon C, Morales J, Lazaro J, Orini M, Deviaene M, Kontaxis S, Testelmans D, Buyse B, Borzee P, Sornmo L, Laguna P, Gil E, Bailon R. A Comparative Study of ECG-derived Respiration in Ambulatory Monitoring using the Single-lead ECG. Sci Rep. 2020 Mar 31;10(1):5704. doi: 10.1038/s41598-020-62624-5. — View Citation
Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | High frequency [HF] (0.15-0.40 Hz) | High frequency (0.15-0.40 Hz), frequency-domain parameter
HF will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Day 1 (T1) | |
Primary | High frequency [HF] (0.15-0.40 Hz) | High frequency (0.15-0.40 Hz), frequency-domain parameter
HF will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 25 days from T1 (T2) | |
Primary | High frequency [HF] (0.15-0.40 Hz) | High frequency (0.15-0.40 Hz), frequency-domain parameter
HF will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 52 days from T1 (T3) | |
Primary | Root mean square of successive RR interval differences [RMSSD] | Root mean square of successive RR interval differences, temporal-domain parameter
RMSSD will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Day 1 (T1) | |
Primary | Root mean square of successive RR interval differences [RMSSD] | Root mean square of successive RR interval differences, temporal-domain parameter
RMSSD will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 25 days from T1 (T2) | |
Primary | Root mean square of successive RR interval differences [RMSSD] | Root mean square of successive RR interval differences, temporal-domain parameter
RMSSD will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 52 days from T1 (T3) | |
Secondary | Low frequency [LF] (0.04-0.15 Hz) | Low frequency (0.04-0.15 Hz), frequency-domain parameter
LF will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Day 1 (T1) | |
Secondary | Low frequency [LF] (0.04-0.15 Hz) | Low frequency (0.04-0.15 Hz), frequency-domain parameter
LF will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 25 days from T1 (T2) | |
Secondary | Low frequency [LF] (0.04-0.15 Hz) | Low frequency (0.04-0.15 Hz), frequency-domain parameter
LF will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 52 days from T1 (T3) | |
Secondary | Low frequency [LF] 0.1 Hertz (0.075-0.108Hz) | Spectral power of the low-frequency 0.1Hz band (0.075-0.108Hz), frequency-domain parameter
LF-0.1Hz will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Day 1 (T1) | |
Secondary | Low frequency [LF] 0.1 Hertz (0.075-0.108Hz) | Spectral power of the low-frequency 0.1Hz band (0.075-0.108Hz), frequency-domain parameter
LF-0.1Hz will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 25 days from T1 (T2) | |
Secondary | Low frequency [LF] 0.1 Hertz (0.075-0.108Hz) | Spectral power of the low-frequency 0.1Hz band (0.075-0.108Hz), frequency-domain parameter
LF-0.1Hz will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 52 days from T1 (T3) | |
Secondary | Total power (0-0.40 Hz) | Total power of the 0-0.40 Hertz band, frequency-domain parameter
Total power will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Day 1 (T1) | |
Secondary | Total power (0-0.40 Hz) | Total power of the 0-0.40 Hertz band, frequency-domain parameter
Total power will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 25 days from T1 (T2) | |
Secondary | Total power (0-0.40 Hz) | Total power of the 0-0.40 Hertz band, frequency-domain parameter
Total power will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 52 days from T1 (T3) | |
Secondary | Ratio Low frequency / High frequency [LF / HF] | Ratio of LF to HF power, frequency-domain parameter
LF/HF will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Day 1 (T1) | |
Secondary | Ratio Low frequency / High frequency [LF / HF] | Ratio of LF to HF power, frequency-domain parameter
LF/HF will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 25 days from T1 (T2) | |
Secondary | Ratio Low frequency / High frequency [LF / HF] | Ratio of LF to HF power, frequency-domain parameter
LF/HF will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 52 days from T1 (T3) | |
Secondary | Standard deviation of all NN intervals [SDNN] | Standard deviation of all NN intervals, temporal-domain parameter
SDNN will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Day 1 (T1) | |
Secondary | Standard deviation of all NN intervals [SDNN] | Standard deviation of all NN intervals, temporal-domain parameter
SDNN will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 25 days from T1 (T2) | |
Secondary | Standard deviation of all NN intervals [SDNN] | Standard deviation of all NN intervals, temporal-domain parameter
SDNN will be measured using the electrocardiogram [ECG]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability [HRV]. |
Up to 52 days from T1 (T3) | |
Secondary | Skin conductance responses [SCR] frequency | Skin conductance responses [SCR] frequency : number of the spontaneous galvanic skin responses by periods
SCR will be measured using the Galvanic skin responses [GSR]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR). |
Day 1 (T1) | |
Secondary | Skin conductance responses [SCR] frequency | Skin conductance responses [SCR] frequency : number of the spontaneous galvanic skin responses by periods
SCR will be measured using the Galvanic skin responses [GSR]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR). |
Up to 25 days from T1 (T2) | |
Secondary | Skin conductance responses [SCR] frequency | Skin conductance responses [SCR] frequency : number of the spontaneous galvanic skin responses by periods
SCR will be measured using the Galvanic skin responses [GSR]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR). |
Up to 52 days from T1 (T3) | |
Secondary | Skin conductance responses [SCR] amplitude | Skin conductance responses amplitude: amplitude of the spontaneous galvanic skin responses by periods
SCR will be measured using the Galvanic skin responses [GSR]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR). |
Day 1 (T1) | |
Secondary | Skin conductance responses [SCR] amplitude | Skin conductance responses amplitude: amplitude of the spontaneous galvanic skin responses by periods
SCR will be measured using the Galvanic skin responses [GSR]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR). |
Up to 25 days from T1 (T2) | |
Secondary | Skin conductance responses [SCR] amplitude | Skin conductance responses amplitude: amplitude of the spontaneous galvanic skin responses by periods
SCR will be measured using the Galvanic skin responses [GSR]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR). |
Up to 52 days from T1 (T3) | |
Secondary | Integrated skin conductance responses [ISCR] | Integrated skin conductance responses [ISCR]: area of the galvanic skin responses identified on the signal
ISCR will be measured using the Galvanic skin responses [GSR]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR). |
Day 1 (T1) | |
Secondary | Integrated skin conductance responses [ISCR] | Integrated skin conductance responses [ISCR]: area of the galvanic skin responses identified on the signal
ISCR will be measured using the Galvanic skin responses [GSR]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR). |
Up to 25 days from T1 (T2) | |
Secondary | Integrated skin conductance responses [ISCR] | Integrated skin conductance responses [ISCR]: area of the galvanic skin responses identified on the signal
ISCR will be measured using the Galvanic skin responses [GSR]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR). |
Up to 52 days from T1 (T3) | |
Secondary | Pulsatility index variation [PI] | Pulsatility index variation [PI] : transit time flow
PI will be measured using the Photoplethysmography [PPG]: PPG data will be recorded using a finger sensor. Physiological data recorded are related to the adrenergic sympathetic tone and allowing a record of the blood pulse waves associated with the heart rate. |
Day 1 (T1) | |
Secondary | Pulsatility index variation [PI] | Pulsatility index variation [PI] : transit time flow
PI will be measured using the Photoplethysmography [PPG]: PPG data will be recorded using a finger sensor. Physiological data recorded are related to the adrenergic sympathetic tone and allowing a record of the blood pulse waves associated with the heart rate. |
Up to 25 days from T1 (T2) | |
Secondary | Pulsatility index variation [PI] | Pulsatility index variation [PI] : transit time flow
PI will be measured using the Photoplethysmography [PPG]: PPG data will be recorded using a finger sensor. Physiological data recorded are related to the adrenergic sympathetic tone and allowing a record of the blood pulse waves associated with the heart rate. |
Up to 52 days from T1 (T3) | |
Secondary | Breathing rate | Breathing rate by cycles per minute
The breathing rate will be measured using a breathing belt. |
Day 1 (T1) | |
Secondary | Breathing rate | Breathing rate by cycles per minute
The breathing rate will be measured using a breathing belt. |
Up to 25 days from T1 (T2) | |
Secondary | Breathing rate | Breathing rate by cycles per minute
The breathing rate will be measured using a breathing belt. |
Up to 52 days from T1 (T3) | |
Secondary | Dominant power (0-0.15Hz) | Dominant power of the 0-0.15 Hertz band, frequency-domain parameter
Dominant power will be measured using the electrogastrogram [EGG]: EGG data will be recorded using 6 single use and adhesive electrodes placed on the skin of the abdomen. |
Day 1 (T1) | |
Secondary | Dominant power (0-0.15Hz) | Dominant power of the 0-0.15 Hertz band, frequency-domain parameter
Dominant power will be measured using the electrogastrogram [EGG]: EGG data will be recorded using 6 single use and adhesive electrodes placed on the skin of the abdomen. |
Up to 25 days from T1 (T2) | |
Secondary | Dominant power (0-0.15Hz) | Dominant power of the 0-0.15 Hertz band, frequency-domain parameter
Dominant power will be measured using the electrogastrogram [EGG]: EGG data will be recorded using 6 single use and adhesive electrodes placed on the skin of the abdomen. |
Up to 52 days from T1 (T3) | |
Secondary | Total power (0-0.15Hz) | Total power of the 0-0.15 Hertz band, frequency-domain parameter
Total power will be measured using the electrogastrogram [EGG]: EGG data will be recorded using 6 single use and adhesive electrodes placed on the skin of the abdomen. |
Day 1 (T1) | |
Secondary | Total power (0-0.15Hz) | Total power of the 0-0.15 Hertz band, frequency-domain parameter
Total power will be measured using the electrogastrogram [EGG]: EGG data will be recorded using 6 single use and adhesive electrodes placed on the skin of the abdomen. |
Up to 25 days from T1 (T2) | |
Secondary | Total power (0-0.15Hz) | Total power of the 0-0.15 Hertz band, frequency-domain parameter
Total power will be measured using the electrogastrogram [EGG]: EGG data will be recorded using 6 single use and adhesive electrodes placed on the skin of the abdomen. |
Up to 52 days from T1 (T3) | |
Secondary | Slow-waves frequency (physiological outcome) | Slow-waves frequency per minute, frequency-domain parameter
Slow-wave frequency will be measured using the electrogastrogram [EGG]: EGG data will be recorded using 6 single use and adhesive electrodes placed on the skin of the abdomen. |
Day 1 (T1) | |
Secondary | Slow-waves frequency (physiological outcome) | Slow-waves frequency per minute, frequency-domain parameter
Slow-wave frequency will be measured using the electrogastrogram [EGG]: EGG data will be recorded using 6 single use and adhesive electrodes placed on the skin of the abdomen. |
Up to 25 days from T1 (T2) | |
Secondary | Slow-waves frequency (physiological outcome) | Slow-waves frequency per minute, frequency-domain parameter
Slow-wave frequency will be measured using the electrogastrogram [EGG]: EGG data will be recorded using 6 single use and adhesive electrodes placed on the skin of the abdomen. |
Up to 52 days from T1 (T3) | |
Secondary | Delta frequency (0-4Hz) | Delta frequency 0-4 Hertz band
Delta frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Day 1 (T1) | |
Secondary | Delta frequency (0-4Hz) | Delta frequency 0-4 Hertz band
Delta frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Up to 25 days from T1 (T2) | |
Secondary | Delta frequency (0-4Hz) | Delta frequency 0-4 Hertz band
Delta frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Up to 52 days from T1 (T3) | |
Secondary | Theta frequency (4-7Hz) | Theta frequency 4-7 Hertz band
Theta frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Day 1 (T1) | |
Secondary | Theta frequency (4-7Hz) | Theta frequency 4-7 Hertz band
Theta frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Up to 25 days from T1 (T2) | |
Secondary | Theta frequency (4-7Hz) | Theta frequency 4-7 Hertz band
Theta frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Up to 52 days from T1 (T3) | |
Secondary | Alpha frequency (8-12Hz) | Alpha frequency 8-12 Hertz band
Alpha frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Day 1 (T1) | |
Secondary | Alpha frequency (8-12Hz) | Alpha frequency 8-12 Hertz band
Alpha frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Up to 25 days from T1 (T2) | |
Secondary | Alpha frequency (8-12Hz) | Alpha frequency 8-12 Hertz band
Alpha frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Up to 52 days from T1 (T3) | |
Secondary | Beta frequency (13-30Hz) | Beta frequency 13-30 Hertz band
Beta frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Day 1 (T1) | |
Secondary | Beta frequency (13-30Hz) | Beta frequency 13-30 Hertz band
Beta frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Up to 25 days from T1 (T2) | |
Secondary | Beta frequency (13-30Hz) | Beta frequency 13-30 Hertz band
Beta frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Up to 52 days from T1 (T3) | |
Secondary | Gamma frequency (>30Hz) | Gamma frequency >30 Hertz band
Gamma frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Day 1 (T1) | |
Secondary | Gamma frequency (>30Hz) | Gamma frequency >30 Hertz band
Gamma frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Up to 25 days from T1 (T2) | |
Secondary | Gamma frequency (>30Hz) | Gamma frequency >30 Hertz band
Gamma frequency will be measured using the electroencephalogram [EEG]: EEG data will be recorded using a EEG headsets including 64 electrodes. The EEG is related to the brain activity generated by the neural functioning. |
Up to 52 days from T1 (T3) | |
Secondary | Alexithymia score | Alexithymia score will be measured using the Bermond-Vorst Alexithymia Questionnaire B version (BVAQ-B; Vorst & Bermond, 2001; French version Deborde et al., 2004). The subscale as considered as a trait scale including 20 items. | Up to 16 days from T2 | |
Secondary | Neuroticism score | Neuroticism score will be measured using the Big Five Inventory-Neuroticism (BFI-N; John et al., 1991; French version Plaisant et al., 2005). The subscale as considered as a trait scale including 8 items. | Up to 16 days from T1 | |
Secondary | Trait and state anxiety scores | The trai and state anxiety scores will be measured using the State-Trait Anxiety Inventory (STAI Y-AB) (Spielberger et al., 1983; French version Bruchon-Schweitzer & Paulhan, 1990). The scale includes 40 items. | Up to 8 days from T1 | |
Secondary | Style of coping | The style of coping will be measured using the Brief Cope (Carver, 1997; French version Muller & Spitz, 2003). We will use it in its trait version. The subscale as considered as a trait scale including 28 items. | Up to 16 days from T1 | |
Secondary | Positive affectivity score | Positive affectivity score will be measured using the Positive And Negative Affect Schedule (PANAS; Watson et al., 1988; French version Caci & Bayle, 2007). To measure a global affective state, a score of positivity will be calculated by subtracting negative affect score from positive affect score. The subscale as considered as a state scale including 20 items. | Day 1 (T1) | |
Secondary | Positive affectivity score | Positive affectivity score will be measured using the Positive And Negative Affect Schedule (PANAS; Watson et al., 1988; French version Caci & Bayle, 2007). To measure a global affective state, a score of positivity will be calculated by subtracting negative affect score from positive affect score. The subscale as considered as a state scale including 20 items. | Up to 25 days from T1 (T2) | |
Secondary | Positive affectivity score | Positive affectivity score will be measured using the Positive And Negative Affect Schedule (PANAS; Watson et al., 1988; French version Caci & Bayle, 2007). To measure a global affective state, a score of positivity will be calculated by subtracting negative affect score from positive affect score. The subscale as considered as a state scale including 20 items. | Up to 52 days from T1 (T3) | |
Secondary | Depressive symptoms score | The depressive symptoms score will be measured using the Center for Epidemiologic Studies-Depression Scale (CES-D; Radloff, 1977; French version Führer & Rouillon, 1989). The subscale as considered as a state scale including 20 items. | Day 1 (T1) | |
Secondary | Depressive symptoms score | The depressive symptoms score will be measured using the Center for Epidemiologic Studies-Depression Scale (CES-D; Radloff, 1977; French version Führer & Rouillon, 1989). The subscale as considered as a state scale including 20 items. | Up to 25 days from T1 (T2) | |
Secondary | Depressive symptoms score | The depressive symptoms score will be measured using the Center for Epidemiologic Studies-Depression Scale (CES-D; Radloff, 1977; French version Führer & Rouillon, 1989). The subscale as considered as a state scale including 20 items. | Up to 52 days from T1 (T3) | |
Secondary | Perceived-stress level | The perceived-stress level will be measured using the Perceived Stress Scale (PSS; Cohen et al., 1983; French version Bellighausen et al., 2009). The subscale as considered as a state scale including 10 items. | Day 1 (T1) | |
Secondary | Perceived-stress level | The perceived-stress level will be measured using the Perceived Stress Scale (PSS; Cohen et al., 1983; French version Bellighausen et al., 2009). The subscale as considered as a state scale including 10 items. | Up to 25 days from T1 (T2) | |
Secondary | Perceived-stress level | The perceived-stress level will be measured using the Perceived Stress Scale (PSS; Cohen et al., 1983; French version Bellighausen et al., 2009). The subscale as considered as a state scale including 10 items. | Up to 52 days from T1 (T3) | |
Secondary | Coping flexibility | The coping flexibility score will be measured using the Coping Flexibility Scale (CFS; Kato, 2012). The CFS measures the coping flexibility including 10 items. The subscale as considered as a state scale. | Day 1 (T1) | |
Secondary | Coping flexibility | The coping flexibility score will be measured using the Coping Flexibility Scale (CFS; Kato, 2012). The CFS measures the coping flexibility including 10 items. The subscale as considered as a state scale. | Up to 25 days from T1 (T2) | |
Secondary | Coping flexibility | The coping flexibility score will be measured using the Coping Flexibility Scale (CFS; Kato, 2012). The CFS measures the coping flexibility including 10 items. The subscale as considered as a state scale. | Up to 52 days from T1 (T3) | |
Secondary | Metacoping | The metacoping score will be measured using a visual analogue scale (VAS). The VAS was developed by ourselves to measure the perceived effectiveness of coping by asking: " how strategies used by yourself to cope with the situation were efficient? ". The participants will have to rate from 0 (no efficacy) to 10 (maximum of efficacy). The subscale as considered as a state scale. | Day 1 (T1) | |
Secondary | Metacoping | The metacoping score will be measured using a visual analogue scale (VAS). The VAS was developed by ourselves to measure the perceived effectiveness of coping by asking: " how strategies used by yourself to cope with the situation were efficient? ". The participants will have to rate from 0 (no efficacy) to 10 (maximum of efficacy). The subscale as considered as a state scale. | Up to 25 days from T1 (T2) | |
Secondary | Metacoping | The metacoping score will be measured using a visual analogue scale (VAS). The VAS was developed by ourselves to measure the perceived effectiveness of coping by asking: " how strategies used by yourself to cope with the situation were efficient? ". The participants will have to rate from 0 (no efficacy) to 10 (maximum of efficacy). The subscale as considered as a state scale. | Up to 52 days from T1 (T3) | |
Secondary | Social support score | The social support score will be measured using the Social Support Questionnaire short version (SSQ6; Sarason et al., 1987a; French version Bruchon-Schweitzer et al., 2003). The subscale as considered as a trait scale including 6 items. | Up to 8 days from T1 | |
Secondary | Interceptive sensitivity score | The interceptive sensitivity score will be measured using the Multidimensional Assessment of Interoceptive Awareness second version (MAIA-2; Mehling et al., 2018). The subscale as considered as a trait scale including 37 items. | Up to 8 days from T1 | |
Secondary | Life satisfaction score | The life satisfaction score will be measured using the Satisfaction With Life Scale (SWLS; Diener et al., 1985; French version Blais et al., 1989). The subscale as considered as a state scale including 5 items. | Day 1 (T1) | |
Secondary | Life satisfaction score | The life satisfaction score will be measured using the Satisfaction With Life Scale (SWLS; Diener et al., 1985; French version Blais et al., 1989). The subscale as considered as a state scale including 5 items. | Up to 25 days from T1 (T2) | |
Secondary | Life satisfaction score | The life satisfaction score will be measured using the Satisfaction With Life Scale (SWLS; Diener et al., 1985; French version Blais et al., 1989). The subscale as considered as a state scale including 5 items. | Up to 52 days from T1 (T3) | |
Secondary | Negative impact scores | The negative impact score will be measured using the Life Experiences Survey (LES; Sarason et al., 1978). The subscale as considered as a trait scale including 50 items. In this study a modified version of the LES will be used, whereby subjects documented the presence and perceived impact of adulthood life events that had occurred since 18 years of age to the time of completion of the survey. For the purposes of this study, 3 scores will be generated from this survey: the number of negatively perceived life events, the negative impact score determined by the sum of the impact scores of negatively perceived life events alone (higher scores indicate greater negative impact), and the total impact score determined by the sum of the impact scores of both negatively and positively perceived life events (higher scores indicate an overall more positive impact and lower scores indicate an overall more negative impact of all adulthood life events). | Up to 16 days from T2 | |
Secondary | Frequency, severity and intensity scores | The frequency, severity and intensity scores will be measured using the Daily Hassles Scale (DHS; Kanner et al., 1981). The subscale as considered as a trait scale including 117 items. | Up to 8 days from T2 | |
Secondary | Child Abuse scores | The child abuse scores will be measured using the Childhood Trauma Questionnaire-Short Form (CTQ; Bernstein et al., 2003). The subscale as considered as a trait scale including 28 items. | Up to 16 days from T1 | |
Secondary | Acceptance score | The acceptance score will be measured using the Illness Cognition Questionnaire for chronic disease (ICQ-18; Evers et al., 2001). The subscale as considered as a state scale including 18 items. | Day 1 (T1) | |
Secondary | Acceptance score | The acceptance score will be measured using the Illness Cognition Questionnaire for chronic disease (ICQ-18; Evers et al., 2001). The subscale as considered as a state scale including 18 items. | Up to 25 days from T1 (T2) | |
Secondary | Acceptance score | The acceptance score will be measured using the Illness Cognition Questionnaire for chronic disease (ICQ-18; Evers et al., 2001). The subscale as considered as a state scale including 18 items. | Up to 52 days from T1 (T3) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |